ClinicalTrials.gg
Not yet recruitingNCT06646796Updated Oct 17, 2024

Yoga Impact in Fibromyalgia, Primary Health Care

An interventional study of Yoga in Fibromyalgia, sponsored by University of Coimbra. Not yet recruiting at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by University of Coimbra · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Fibromyalgia with a site in Portugal — 2 open to participants now, 2 under way, none of them phase 3. Fibromyalgia · Portugal.

Planned enrollment
10th of 13
20 · median 60
Started
2024
with 1 other
No phase
7 of 14
2 open now
Registered
10th of 14
by date
Lead sponsor
2 of 14
University of Coimbra

Among the 14 studies in Fibromyalgia with a site in Portugal, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2024, is one of 7 with no phase, and was the 10th registered.

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

2 of the 14 studies in Fibromyalgia with a site in Portugal are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Fibromyalgia with a site in Portugal, or all of them as a file.
02

Study summary

This study aims to evaluate the effectiveness of a complementary therapy using Yoga within the scope of First Health Care in Portugal, in pain control, quality of life and well-being of the patients with Fibromyalgia. It also, pretends to assess the viability and to identify the barriers to this sort of therapy in the context of Primary Health Care.

Read the detailed description

Fibromyalgia is a chronic and debilitating pain syndrome characterized by widespread and persistent pain, also affecting sleep quality and cognitive function. It is estimated to affect 3.6% of the population; however, since it is a condition that is often underdiagnosed, the actual numbers may be higher. It is also an incurable disease, so treatment is based on symptom management through pharmacological therapy, which is not always effective. Due to the inadequacy of pharmacological therapy, there is a need for complementary therapies, and despite the limited number of studies conducted in this area, some therapies based on meditative movement (notably yoga) are beginning to emerge, with beneficial effects reported on pain management and quality of life in these patients. Therefore, this study aims to investigate the benefits and feasibility of this type of intervention at the Primary Health Care level.

03

Conditions studied

  • Fibromyalgia

Keywords

  • Fibromyalgia
  • Chronic pain
  • Yoga
  • Complementary and alternative medicine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Users of the Family Health Unit diagnosed with Fibromyalgia;
  • With cognitive capacity to answer the questionnaire;
  • With physical capacity to take part in Yoga classes.

Exclusion criteria

Exclusion Criteria:

  • people under 18 years old.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • No intervention
    Control group

    Group used as comparison.

  • Experimental
    Intervention group

    Yoga practioner group with a certified teacher, 3 times a week during 3 months.

    Other: Yoga

Interventions

  • OtherYoga

    Yoga with certified teacher, 3 times a week during 3 months.

06

What researchers measure

Primary outcomes

  1. Quality of Life

    EQ-5D

    Time frame: at the beggining and up to 3 months

  2. Pain

    Visual scale from 0 to 10 to measure pain

    Time frame: at the beggining and up to 3 months

  3. Global perception of change

    Patient Global Impression of Change scale (portuguese validated version) 1 to 7 (1 is the worst, 7 is the best)

    Time frame: up to 3 months

Secondary outcomes

  1. Well-being

    EADS-21

    Time frame: at the beggining and up to 3 months

  2. Benefits perceived

    Open question answered by the patients trough a written text

    Time frame: up to 3 months

  3. Difficulties perceived

    Open question answered by the patients trough a written text

    Time frame: up to 3 months

  4. Replicability and ease of introducing treatment in the context of the Portuguese national health service

    Open questions and SWOT analysis

    Time frame: up to 3 months

07

Study locations

1 site
  • USF Coimbra Centro
    Coimbra, 3000-174, Portugal
08

References and documents

Publications

  • Cabo-Meseguer A, Cerda-Olmedo G, Trillo-Mata JL. Fibromyalgia: Prevalence, epidemiologic profiles and economic costs. Med Clin (Barc). 2017 Nov 22;149(10):441-448. doi: 10.1016/j.medcli.2017.06.008. Epub 2017 Jul 19. English, Spanish. PubMed 28734619 ↗
  • Prabhakar A, Kaiser JM, Novitch MB, Cornett EM, Urman RD, Kaye AD. The Role of Complementary and Alternative Medicine Treatments in Fibromyalgia: a Comprehensive Review. Curr Rheumatol Rep. 2019 Mar 4;21(5):14. doi: 10.1007/s11926-019-0814-0. PubMed 30830504 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2024; primary completion for Feb 2025, 2 months later.

Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's planned 2 months is below that.

Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2024
First posted
Oct 17, 2024
StartEst.
Dec 1, 2024
Primary completionEst.
Feb 28, 2025
CompletionEst.
Apr 30, 2025
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06646796
Lead sponsor
University of Coimbra
Responsible party
Ines Rosendo (PhD, University of Coimbra) — Principal investigator
First posted
Oct 17, 2024
Start date
Dec 1, 2024 (estimated)
Primary completion
Feb 28, 2025 (estimated)
Completion
Apr 30, 2025 (estimated)
Last update
Oct 17, 2024

Study contacts

Inês Rosendo Silva, MD PhD
Contact
inesrcs@gmail.com
(351) 918-4186

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion